Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Buy” from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been assigned a consensus rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $23.83.

ACRV has been the topic of a number of research reports. BMO Capital Markets restated an “outperform” rating and issued a $28.00 price target (up from $25.00) on shares of Acrivon Therapeutics in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Acrivon Therapeutics in a research report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price objective on shares of Acrivon Therapeutics in a report on Monday, September 16th. Piper Sandler Companies reaffirmed a “buy” rating and set a $30.00 target price on shares of Acrivon Therapeutics in a report on Friday, September 6th. Finally, LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Monday, September 16th.

Institutional Trading of Acrivon Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its position in Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock worth $31,093,000 after purchasing an additional 2,353,000 shares during the last quarter. Sands Capital Ventures LLC increased its holdings in Acrivon Therapeutics by 28.4% during the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock worth $12,311,000 after purchasing an additional 470,000 shares during the period. Marshall Wace LLP raised its holdings in shares of Acrivon Therapeutics by 58.8% in the second quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after acquiring an additional 351,397 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Acrivon Therapeutics by 6.6% during the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock valued at $3,626,000 after purchasing an additional 31,208 shares in the last quarter. Finally, Baker BROS. Advisors LP purchased a new position in Acrivon Therapeutics in the first quarter valued at about $378,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Trading Up 1.9 %

ACRV stock opened at $8.39 on Wednesday. The stock has a market capitalization of $259.84 million, a PE ratio of -3.03 and a beta of 0.66. The stock’s 50 day simple moving average is $7.81 and its 200 day simple moving average is $7.81. Acrivon Therapeutics has a 12-month low of $3.19 and a 12-month high of $11.90.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.08. On average, research analysts predict that Acrivon Therapeutics will post -2.4 earnings per share for the current year.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.